Switzerland’s basic health insurance started reimbursing part of the cost of Wegovy, a weight-loss drug developed by Danish pharmaceutical giant Novo Nordisk. The decision has led to ...

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...